Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23943816 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4PRCPHTR2AHTR2C | |
| SCHEMBL25354904 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4PRCPHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL4024877 | 0.98 | SLC6A2 (0.37) | SLC6A2SLC6A4PRCPHTR2AHTR2C | |
| SCHEMBL23057911 | 0.78 | TAAR1 (0.43) | SLC6A2SLC6A4PRCP | |
| SCHEMBL29589340 | 0.78 | TAAR1 (0.43) | SLC6A2SLC6A4PRCP | |
| SCHEMBL29588263 | 0.78 | TAAR1 (0.43) | SLC6A2SLC6A4PRCP | |
| SCHEMBL23323076 | 0.78 | TAAR1 (0.43) | SLC6A2SLC6A4PRCP | |
| SCHEMBL23323218 | 0.78 | TAAR1 (0.43) | SLC6A2SLC6A4PRCP | |
| SCHEMBL7332257 | 0.77 | HTR2C (0.50) | HTR2AHTR2CHTR2B | |
| SCHEMBL20139212 | 0.77 | HTR2C (0.50) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| CN-119365456-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| EP-4442685-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024032755-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023231777-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2023-12-07 | — | — | WO | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023104043-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | 杭州和正医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116217566-A | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | SLC6A2 4423/4885SLC6A4 4343/4885PRCP 3938/4885 |
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | SLC6A2 4410/4885SLC6A4 4772/4885PRCP 2550/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | SLC6A2 4410/4885SLC6A4 4772/4885PRCP 2550/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | SLC6A2 4859/4885SLC6A4 4875/4885PRCP 1473/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | SLC6A2 4410/4885SLC6A4 4772/4885PRCP 2550/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | SLC6A2 4410/4885SLC6A4 4772/4885PRCP 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.